4.7 Article

Current Compound Coverage of the Kinome

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 58, Issue 1, Pages 30-40

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/jm5008159

Keywords

-

Funding

  1. Jurgen Manchot Foundation, Dusseldorf, Germany

Ask authors/readers for more resources

Publicly available kinase inhibitors have been analyzed in detail. Nearly 19000 inhibitors have been identified with activity against 266 different kinases. Thus, about half of the human kinome is currently covered with active small molecules. The distribution of inhibitors across the kinome is uneven. Most available kinase inhibitors are likely to be type I inhibitors. By contrast, type II inhibitors are rare but usually have high potency. Kinase inhibitors generally display high scaffold diversity. Activity cliffs with an at least 100-fold difference in potency are only found for inhibitors of 106 kinases, which is partly due to only small numbers of compounds available for many kinases, in addition to scaffold diversity. Moreover, kinase inhibitors are less promiscuous than often thought. More than 70% of available inhibitors are only annotated with a single kinase activity, and only similar to 1% of the inhibitors are active against five or more kinases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Identification of Interaction Hot Spots in Structures of Drug Targets on the Basis of Three-Dimensional Activity Cliff Information

Norbert Furtmann, Ye Hu, Michael Guetschow, Juergen Bajorath

CHEMICAL BIOLOGY & DRUG DESIGN (2015)

Article Chemistry, Multidisciplinary

Limiting the Number of Potential Binding Modes by Introducing Symmetry into Ligands: Structure-Based Design of Inhibitors for Trypsin-Like Serine Proteases

Norbert Furtmann, Daniela Haeussler, Tamara Scheidt, Marit Stirnberg, Torsten Steinmetzer, Juergen Bajorath, Michael Guetschow

CHEMISTRY-A EUROPEAN JOURNAL (2016)

Article Chemistry, Medicinal

Active Site Mapping of Human CathepsinF with Dipeptide Nitrile Inhibitors

Janina Schmitz, Norbert Furtmann, Moritz Ponert, Maxim Frizler, Reik Loeser, Ulrike Bartz, Juergen Bajorath, Michael Guetschow

CHEMMEDCHEM (2015)

Review Chemistry, Medicinal

Structural and Modeling Studies on ecto-5′-nucleotidase Aiding in Inhibitor Design

Norbert Furtmann, Juergen Bajorath

MINI-REVIEWS IN MEDICINAL CHEMISTRY (2015)

Article Chemistry, Organic

Design, characterization and cellular uptake studies of fluorescence-labeled prototypic cathepsin inhibitors

Franziska Kohl, Janina Schmitz, Norbert Furtmann, Anna-Christina Schulz-Fincke, Matthias D. Mertens, Jim Kueppers, Marcel Benkhoff, Edda Tobiasch, Ulrike Bartz, Jurgen Bajorath, Marit Stirnberg, Michael Guetschow

ORGANIC & BIOMOLECULAR CHEMISTRY (2015)

Article Chemistry, Organic

Oxidation of Disulfides to Taurine and Sulfanilic Acid Derivatives

Norbert Furtmann, Erik Gilberg, Nicola Spuetz, Michael Guetschow

SYNTHESIS-STUTTGART (2015)

Article Chemistry, Multidisciplinary

Identification and analysis of the currently available high-confidence three-dimensional activity cliffs

Norbert Furtmann, Ye Hu, Michael Guetschow, Juergen Bajorath

RSC ADVANCES (2015)

Article Biochemistry & Molecular Biology

Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors

Aliya Ibrar, Yildiz Tehseen, Imtiaz Khan, Abdul Hameed, Aamer Saeed, Norbert Furtmann, Juergen Bajorath, Jamshed Iqbal

BIOORGANIC CHEMISTRY (2016)

Article Biochemistry & Molecular Biology

En Route to New Therapeutic Options for Iron Overload Diseases: Matriptase-2 as a Target for Kunitz-Type Inhibitors

Anna-Madeleine Beckmann, Eva Maurer, Verena Luelsdorff, Annika Wilms, Norbert Furtmann, Juergen Bajorath, Michael Guetschow, Marit Stirnberg

CHEMBIOCHEM (2016)

Article Chemistry, Multidisciplinary

Phosphono Bisbenzguanidines as Irreversible Dipeptidomimetic Inhibitors and Activity-Based Probes of Matriptase-2

Daniela Haeussler, Martin Mangold, Norbert Furtmann, Annett Braune, Michael Blaut, Juergen Bajorath, Marit Stirnberg, Michael Guetschow

CHEMISTRY-A EUROPEAN JOURNAL (2016)

Article Microbiology

Chalcone Isomerase from Eubacterium ramulus Catalyzes the Ring Contraction of Flavanonols

Annett Braune, Wolfram Engst, Paul W. Elsinghorst, Norbert Furtmann, Juergen Bajorath, Michael Guetschow, Michael Blaut

JOURNAL OF BACTERIOLOGY (2016)

Article Multidisciplinary Sciences

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections

Wanwisa Promsote, Ling Xu, Jason Hataye, Giulia Fabozzi, Kylie March, Cassandra G. Almasri, Megan E. DeMouth, Sarah E. Lovelace, Chloe Adrienna Talana, Nicole A. Doria-Rose, Krisha McKee, Sabrina Helmold Hait, Joseph P. Casazza, David Ambrozak, Jochen Beninga, Ercole Rao, Norbert Furtmann, Joerg Birkenfeld, Elizabeth McCarthy, John-Paul Todd, Constantinos Petrovas, Mark Connors, Andrew T. Hebert, Jeremy Beck, Junqing Shen, Bailin Zhang, Mikhail Levit, Ronnie R. Wei, Zhi-yong Yang, Amarendra Pegu, John R. Mascola, Gary J. Nabel, Richard A. Koup

Summary: Researchers have developed a trispecific antibody that can activate and target latently HIV-1 infected cells for elimination by T cells, providing an alternative strategy for curing HIV.

NATURE COMMUNICATIONS (2023)

Article Chemistry, Multidisciplinary

Extension of three-dimensional activity cliff information through systematic mapping of active analogs

Ye Hu, Norbert Furtmann, Juergen Bajorath

RSC ADVANCES (2015)

No Data Available